Study report--clinical application of Ga-67 DFO-DAS-fibrinogen.
The purpose of this study was to apply a new radiopharmaceutical for thrombus imaging. Forty patients with thrombus, including 18 with aortic aneurysm and seven with graft replacement, were studied using the planar imaging technique. Thrombus imagings were obtained 6-96 hours after intravenous administration of 2 mCi of 67Ga-DFO-DAS-fibrinogen (67Ga-fibrinogen). The best images were achieved 48-96 hours after 67Ga-fibrinogen administration. Twenty-one of 40 patients with proven thrombus had positive planar images. A high positive ratio (83%) was obtained in patients with aortic aneurysm. In the remaining patients, the planar images were interpreted as showing no evidence of active thrombus formation of fibrinogen. These studies demonstrate the potential of 67Ga-fibrinogen for the noninvasive localization of active thrombi.
Kusakabe
K
K
Department of Radiology, Tokyo Women's Medical College, Japan.
Kawasaki
Y
Y
D000328:Adult; D000368:Aged; D003676:Deferoxamine / Q000627:therapeutic use; D005260:Female; D005340:Fibrinogen; D005710:Gallium Radioisotopes; D006801:Humans; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D013213:Starch / Q000031:analogs & derivatives; D013924:Thrombophlebitis / Q000000981:diagnostic imaging; D013927:Thrombosis / Q000000981:diagnostic imaging*
D005710:Gallium Radioisotopes; D005340:Fibrinogen; D013213:Starch; C012880:dialdehyde starch; D003676:Deferoxamine